Charles Schwab Investment Management Inc Actinium Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 76,208 shares of ATNM stock, worth $563,939. This represents 0.0% of its overall portfolio holdings.
Number of Shares
76,208
Previous 76,208
-0.0%
Holding current value
$563,939
Previous $387,000
54.01%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ATNM
# of Institutions
72Shares Held
6.65MCall Options Held
369KPut Options Held
148K-
Black Rock Inc. New York, NY1.71MShares$12.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.45MShares$10.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA596KShares$4.41 Million0.0% of portfolio
-
State Street Corp Boston, MA551KShares$4.08 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL231KShares$1.71 Million0.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $186M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...